Charlie Bu

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin et al. · Molecular Cancer Therapeutics · 2021 · 75 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy et al. · Molecular Cancer Therapeutics · 2021 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Guoqing Tang, Yalan Tang, Ketki Dhamnaskar et al. · Frontiers in Immunology · 2023 · 43 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Abstract 48: Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate

Alex Yurkovetskiy, Dmitry R. Gumerov, Elena Ter‐Ovanesyan et al. · Cancer Research · 2017 · 14 citations

Pharmacy, Oncology, Pharmacology +17